According to a new paper published by the team behind the PsoProtect registry, psoriasis patients treated with biologics are at a lower risk of being hospitalized due to COVID-19 than those treated with non-biologic systemic therapies.
Read the full article here:
Factors associated with adverse COVID-19 outcomes in patients with psoriasis - insights from a global registry-based study